PubMed Health. A service of the National Library of Medicine, National Institutes of Health.

Malottki K, Barton P, Tsourapas A, et al. Adalimumab, Etanercept, Infliximab, Rituximab and Abatacept for the Treatment of Rheumatoid Arthritis After the Failure of a Tumour Necrosis Factor Inhibitor: A Systematic Review and Economic Evaluation. Southampton (UK): NIHR Journals Library; 2011 Mar. (Health Technology Assessment, No. 15.14.)

Appendix 2Literature search strategies

Source – Cochrane Library (CENTRAL, DARE and NHS EED) 2009 Issue 3

# 1.

rheumatoid next arthritis

# 2.

MeSH descriptor Arthritis, Rheumatoid explode all trees

# 3.

(#1 OR #2)

# 4.

adalimumab or humira

# 5.

etanercept or enbrel

# 6.

infliximab or remicade

# 7.

rituximab or mabthera

# 8.

abatacept or orencia

# 9.

(#4 OR #5 OR #6 OR #7 OR #8)

# 10.

(#3 AND #9)

Source – MEDLINE (Ovid) 1950 – July Week 1 2009

  1. arthritis rheumatoid/ (68,937)
  2. or/1-2 (83,478)
  3. (adalimumab or humira).mp. (1,199)
  4. (etanercept or enbrel).mp. (2,138)
  5. (rituximab or mabthera).mp. (5,052)
  6. (abatacept or orencia).mp. (1,779)
  7. (infliximab or remicade).mp. (4,830)
  8. or/4-8 (13,083)
  9. 3 and 9 (2,759)

Source – MEDLINE(Ovid) In-Process & Other Non-Indexed Citations 13 July, 2009

11.

(adalimumab or humira).mp. (129)

12.

(etanercept or enbrel).mp. (203)

13.

(rituximab or mabthera).mp. (455)

14.

(abatacept or orencia).mp. (39)

15.

(infliximab or remicade).mp. (346)

16.

or/1-5 (990)

17.

rheumatoid arthritis.tw. (1,987)

18.

6 and 7 (220)

Source – EMBASE (Ovid) 1980 to 2009 Week 28

19.

(adalimumab or humira).ti,ab,sh. (4,120)

20.

(etanercept or enbrel).ti,ab,sh. (8,362)

21.

(rituximab or mabthera).ti,ab,sh. (12,634)

22.

(abatacept or orencia).ti,ab,sh. (1,014)

23.

(infliximab or remicade).ti,ab,sh. (12,117)

24.

or/1-5 (26,879)

25.

rheumatoid arthritis/ (59,837)

26.

rheumatoid arthritis.tw. (47,871)

27.

7 or 8 (68,003)

28.

6 and 9 (6,262)

© 2011, Crown Copyright.

Included under terms of UK Non-commercial Government License.

Cover of Adalimumab, Etanercept, Infliximab, Rituximab and Abatacept for the Treatment of Rheumatoid Arthritis After the Failure of a Tumour Necrosis Factor Inhibitor: A Systematic Review and Economic Evaluation
Adalimumab, Etanercept, Infliximab, Rituximab and Abatacept for the Treatment of Rheumatoid Arthritis After the Failure of a Tumour Necrosis Factor Inhibitor: A Systematic Review and Economic Evaluation.
Health Technology Assessment, No. 15.14.
Malottki K, Barton P, Tsourapas A, et al.
Southampton (UK): NIHR Journals Library; 2011 Mar.

Download

PubMed Health Blog...

read all...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...